RT Journal Article
T1 Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions.
A1 López-Campos, Fernando
A1 Gajate, Pablo
A1 Romero-Laorden, Nuria
A1 Zafra-Martín, Juan
A1 Juan, Manel
A1 Hernando Polo, Susana
A1 Conde Moreno, Antonio
A1 Couñago, Felipe
K1 advanced prostate cancer
K1 cancer vaccines
K1 immune checkpoints inhibitors
K1 immunotherapy
K1 metastatic castration-resistant prostate cancer
AB The advent of immunotherapy has revolutionized cancer treatment. Unfortunately, this has not been the case for metastatic castration-resistant prostate cancer (mCRPC), likely due to the heterogeneous and immune-suppressive microenvironment present in prostate cancer. The identification of molecular biomarkers that could predict response to immunotherapy represents one of the current challenges in this clinical scenario. The management of advanced castration-resistant prostate cancer is rapidly evolving and immunotherapy treatments, mostly consisting of immune checkpoint inhibitors combinations, BiTE® (bispecific T-cell engager) immune therapies, and chimeric antigen receptors (CAR) are in development with promising results. This review analyses the current evidence of immunotherapy treatments for mCRPC, evaluating past failures and promising approaches and discussing the directions for future research.
SN 2227-9059
YR 2022
FD 2022-02-24
LK http://hdl.handle.net/10668/20821
UL http://hdl.handle.net/10668/20821
LA en
DS RISalud
RD Apr 17, 2025